Contact Information
Department of Biochemistry and Molecular Biomedicine
Avinguda Diagonal 643, Facultat de Biologia, Edifici Prevosti planta -2 934021217 mtarrado(a)ub.edu
Academic Training
Bachelor of Science degree in Chemical Engineering
. Facultat de Química, Universitat de Barcelona
. 06/2011
. (Diploma / Degree / Activities)Bachelor of Science degree in Biochemistry
. Facultat de Biologia, Universitat de Barcelona
. 06/2009
. (Diploma / Degree / Activities)PhD in Biotechnology
. Facultat de Biologia, Universitat de Barcelona
. 11/12/2015
. (Ph.D.)Master in Molecular Biotechnology
. Facultat de Farmàcia, Universitat de Barcelona
. 09/2010
. (Official Master)
Research interests
Targeting metabolic reprogramming associated to cancer cells: search of novel targets and combined therapies in cancer treatmentOvercoming acquired drug resistance driven by metabolic reprogramming in colorectal and prostate cancerCaracterització de les adaptacions metabòliques en càncer de còlon i de l'efecte antitumoral de nous inhibidors sintètics i/o derivats de productes naturals
Projects
Análisis de la reprogramación metabólica metastásica en la búsqueda de nuevas estrategias terapéuticas en cáncer
.
2015 - 2017
. Ref.SAF2014-56059-R
. Ministerio de Economia y Competitividad
. PI: Marta Cascante SerratosaCENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER)
.
2018 - 2023
. Ref.CB17/04/00023
. Ministerio de Economia y Competitividad
. PI: Marta Cascante SerratosaTargeting metabolic reprogramming to overcome acquired therapeutic resistance in colorectal cancer
.
2020 - 2023
. Ref.EHD20PI03
. Consorcio CIBER del área de Enfermedades Hepáticas y Digestivas (CIBEREHD)
. PI: Míriam Tarrado CastellarnauNEUTRALIZACIÓN DE LA REPROGRAMACIÓN METABÓLICA ASOCIADA A LA METÁSTASIS Y A LA RESISTENCIA AL TRATAMIENTO PARA PREVENIR EL FRACASO TERAPÉUTICO EN CANCER DE PROSTATA Y COLON
.
2018 - 2020
. Ref.SAF2017-89673-R
. Ministerio de Ciencia, Innovación y Universidades
. PI: Marta Cascante SerratosaIdentificación de los subtipos metabólicos de cáncer colorrectal para el desarrollo de medicina personalizada
.
2021 - 2024
. Ref.PID2020-115051RB-I00
. Ministerio de Ciencia e Innovación (MICINN)
. PI: Marta Cascante Serratosa; Pedro Ramon de Atauri Carulla
Journal Publications
Tarrado-Castellarnau, M.; Cortés, R.; Zanuy, M.; Tarragó-Celada, J.; Polat, I.H.; Hill, R.; Fan, T.W.; Link, W.; Cascante, M.(2015).
Methylseleninic acid promotes Antitumour effects via nuclear FOXO3a translocation through Akt inhibition.Pharmacological Research, 102, pp. 218 - 234
. Institutional Repository. ISSN: 1043-6618Cortes, R.; Tarrado-Castellarnau, M.; Talancón, D.; López, C.; Link, W.; Ruiz, D.; D.; Centelles, J.; Quirantee, J.; Cascante, M.(2014).
A novel cyclometallated Pt(II) ferrocene complex induces nuclear FOXO3a localization and Q2 apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation.Metallomics, 6(3), pp. 622 - 633
. https://doi.org/10.1039/c3mt00194f. ISSN: 1756-5901Diaz-Moralli, S.; Tarrado-Castellarnau, M.; Miranda, A.; Cascante, M.(2013).
Targeting Cell cycle regulation in cancer therapy.Pharmacology & Therapeutics, 138(2), pp. 255 - 271
. https://doi.org/10.1016/j.pharmthera.2013.01.011. ISSN: 0163-7258Tarrado-Castellarnau, M.; de Atauri, P.; Cascante, M.(2016).
Oncogenic regulation of tumor metabolic reprogramming.Oncotarget, 7(38), pp. 62726 - 62753
. Institutional Repository. ISSN: 1949-2553Tarrado-Castellarnau, M.; Diaz-Moralli, S.; Polat, I.H.; Sanz-Pamplona, R.; Alenda, C.; Moreno, V.; Castells, A.; Cascante, M.(2017).
Glyceraldehyde-3-phosphate dehydrogenase is overexpressed in colorectal cancer onset.Translational Medicine Communications, 2(6), pp. 1 - 9
. Institutional Repository. ISSN: 2396-832XTarrado-Castellarnau, M.; de Atauri, P.; Tarragó-Celada, J.; Perarnau, J.; Yuneva, M.; Thomson T.M.; Cascante, M.(2017).
De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition.Molecular Systems Biology, 13(10), p. 940
. Institutional Repository. ISSN: 1744-4292Tarragó-Celada,Josep; Foguet,Carles; Tarrado-Castellarnau,Míriam ; Marin, Silvia; Hernández-Alias,Xavier; Perarnau, Jordi; Morrish,Fionnuala; Hockenbery, David; Gomis,Roger R.; Ruppin,Eytan; Yuneva,Mariia; Atauri, Pedro de; Cascante,Marta(2021).
Cysteine and Folate metabolism are targetable vulnerabilities of metastatic colorectal cancer.Cancers, 13(3), p. 425
. Institutional Repository. ISSN: 2072-6694Polat, Ibrahim H.; Tarrado-Castellarnau, Míriam; Bharat, Rohit; Perarnau, Jordi; Benito, Adrian; Cortés, Roldán; Sabatier, Philippe; Cascante, Marta(2021).
Oxidative pentose phosphate pathway enzyme 6-phosphogluconate dehydrogenase plays a key role in breast cancer metabolism.Biology, 10(2), p. 85
. Institutional Repository. ISSN: 2079-7737de Atauri P.; Tarrado-Castellarnau M.; Tarragó-Celada J.; Foguet C.; Karakitsou E.; Centelles J.J.; Cascante M.(2021).
Integrating systemic and molecular levels to infer key drivers sustaining metabolic adaptations.PLoS Computational Biology, 17(7), p. e1009234
. Institutional Repository. ISSN: 1553-734XPolat, Ibrahim H.; Tarrado Castellarnau, Míriam Neus; Benito Mauricio, Adrián; Hernández Carro, Claudia; Centelles Serra, Josep Joan; Marin, Silvia; Cascante i Serratosa, Marta(2021).
Glutamine modulates expression and function of glucose 6-phosphate dehydrogenase via NRF2 in colon cancer cells.Antioxidants, 10(9), pp. 1 - 16
. Institutional Repository. ISSN: 2076-3921